Patents by Inventor Naoko Hata

Naoko Hata has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7834049
    Abstract: The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action.
    Type: Grant
    Filed: April 4, 2005
    Date of Patent: November 16, 2010
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Toshiaki Wakabayashi, Yasuhiro Funahashi, Naoko Hata, Taro Semba, Yuji Yamamoto, Toru Haneda, Takashi Owa, Akihiko Tsuruoka, Junichi Kamata, Tadashi Okabe, Keiko Takahashi, Kazumasa Nara, Shinichi Hamaoka, Norihiro Ueda
  • Publication number: 20100267754
    Abstract: The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action.
    Type: Application
    Filed: June 10, 2010
    Publication date: October 21, 2010
    Inventors: Toshiaki WAKABAYASHI, Yasuhiro Funahashi, Naoko Hata, Taro Semba, Yuji Yamamoto, Toru Haneda, Takashi Owa, Akihiko Tsuruoka, Junichi Kamata, Tadashi Okabe, Keiko Takahashi, Kazumasa Nara, Shinichi Hamaoka, Norihiro Ueda
  • Publication number: 20100086931
    Abstract: An object of the present invention is to provide a method, a probe, a primer, an antibody, a reagent, and a kit for assaying an action of a pladienolide derivative to a living subject. According to the present invention, there is provided a method for assaying an action of the pladienolide derivative using a decrease in gene expression level as an index.
    Type: Application
    Filed: March 5, 2008
    Publication date: April 8, 2010
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Yoshiharu Mizui, Naoko Hata, Masao Iwata, Rie Sugano, Naoki Toritsuka, Taku Yoshida, Mai Uesugi, Tadashi Kadowaki
  • Publication number: 20100021918
    Abstract: An object of the present invention is to provide a method, a probe, a primer, an antibody, a reagent, and a kit for assaying an action of a pladienolide derivative to a living subject. According to the present invention, there is provided a method for assaying an action of the pladienolide derivative using splicing defect as an index.
    Type: Application
    Filed: March 5, 2008
    Publication date: January 28, 2010
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Yoshiharu Mizui, Naoko Hata, Masao Iwata, Koji Sagane, Mai Uesugi, Tadashi Kadowaki, Taku Yoshida
  • Publication number: 20090047365
    Abstract: The present invention relates to a pharmaceutical composition, a kit, a method of treating cancer and/or a method of inhibiting angiogenesis comprising a sulfonamide compound in combination with a platinum complex, a DNA-topoisomerase I inhibitor, an antimetabolite, a microtubule inhibitor or an antibiotic.
    Type: Application
    Filed: February 28, 2006
    Publication date: February 19, 2009
    Applicant: Eisai R & D Management Co., Ltd.
    Inventors: Takashi Owa, Yoichi Ozawa, Taro Semba, Naoko Hata
  • Publication number: 20080286282
    Abstract: The present invention relates to a pharmaceutical composition, a kit and a method for treating cancer and/or a method for inhibiting angiogenesis, comprising a sulfonamide compound in combination with Bevacizumab.
    Type: Application
    Filed: February 28, 2006
    Publication date: November 20, 2008
    Applicant: Eisai R & D Management Co., Ltd.
    Inventors: Taro Semba, Naoko Hata, Yoichi Ozawa, Takashi Owa
  • Patent number: 7122318
    Abstract: The present invention provides a system for testing the influence of a drug on integrin expression, which comprises measuring an integrin expression level in platelets of an individual to which the drug is administered and, based on the measured expression amount, determining what effect the drug has on integrin expression in cells other than platelets.
    Type: Grant
    Filed: February 21, 2002
    Date of Patent: October 17, 2006
    Assignee: Eisai Co., Ltd.
    Inventors: Naoto Ono, Taro Senba, Naoko Hata, Yasuhiro Funahashi, Toshiaki Wakabayashi
  • Patent number: 7015241
    Abstract: An appetite-stimulating agent and a therapeutic agent for anorexia, each comprising, as an active ingredient, a sulfonamide derivative or sulfonic acid ester derivative represented by the following general formula (I): wherein the ring A represents a monocyclic or bicyclic aromatic ring which may be substituted, the ring B represents a 6-membered unsaturated hydrocarbon ring or a 6-membered unsaturated heterocyclic ring containing one nitrogen atom as a heteroatom, each of which may be substituted, the ring C represents a 5-membered heterocyclic ring containing one or two nitrogen atoms, which may be substituted, W represents a single bond or —CH?CH—, X represents —N(R1)— or an oxygen atom, Y represents a carbon atom or a nitrogen atom, Z represents —N(R2)— or a nitrogen atom, and R1 and R2 may be identical or different and each represents a hydrogen atom or a lower alkyl group, or a pharmacologically acceptable salt thereof, or a hydrate thereof.
    Type: Grant
    Filed: September 5, 2002
    Date of Patent: March 21, 2006
    Assignee: Eisai Co., Ltd.
    Inventors: Takashi Owa, Yoichi Ozawa, Takayuki Hida, Norimasa Miyamoto, Takeshi Nagasu, Tatsuo Okauchi, Hiroshi Yoshino, Naoko Hata, Kentaro Yoshimatsu, Nozomu Koyanagi, Kyosuke Kito
  • Publication number: 20050176712
    Abstract: The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action.
    Type: Application
    Filed: April 4, 2005
    Publication date: August 11, 2005
    Inventors: Toshiaki Wakabayashi, Yasuhiro Funahashi, Naoko Hata, Taro Semba, Yuji Yamamoto, Toru Haneda, Takashi Owa, Akihiko Tsuruoka, Junichi Kamata, Tadashi Okabe, Keiko Takahashi, Kazumasa Nara, Shinichi Hamaoka, Norihiro Ueda
  • Publication number: 20040242628
    Abstract: An appetite-stimulating agent and a therapeutic agent for anorexia, each comprising, as an active ingredient, a sulfonamide derivative or sulfonic acid ester derivative represented by the following general formula (I): 1
    Type: Application
    Filed: March 5, 2004
    Publication date: December 2, 2004
    Inventors: Takashi Owa, Yoichi Ozawa, Takayuki Hida, Norimasa Miyamoto, Takeshi Nagasu, Tatsuo Okauchi, Hiroshi Yoshino, Naoko Hata, Kentaro Yoshimatsu, Nozomu Koyanagi, Kyosuke Kito
  • Patent number: 6787534
    Abstract: The present invention provides a sulfonamide- or sulfonylurea-containing heterocyclic compounds. Specifically, it provides a heterocyclic compound represented by the formula (I), a pharmacologically acceptable salt thereof or a hydrate of them.
    Type: Grant
    Filed: June 10, 2002
    Date of Patent: September 7, 2004
    Assignee: Eisai Co., Ltd.
    Inventors: Toru Haneda, Akihiko Tsuruoka, Junichi Kamata, Tadashi Okabe, Keiko Takahashi, Kazumasa Nara, Shinichi Hamaoka, Norihiro Ueda, Toshiaki Wakabayashi, Yasuhiro Funahashi, Taro Semba, Naoko Hata, Yuji Yamamoto, Yoichi Ozawa, Naoko Tsukahara, Takashi Owa
  • Publication number: 20040132783
    Abstract: A method for testing influence of a drug on integrin expression, which comprises the step of measuring an integrin expression amount in platelets of a patient to which the drug is administered and the step of determining influence of the drug on integrin expression in cells other than platelets based on the measured expression amount.
    Type: Application
    Filed: January 20, 2004
    Publication date: July 8, 2004
    Inventors: Naoto Ono, Taro Senba, Naoko Hata, Yasuhiro Funahashi, Toshiaki Wakabayashi
  • Publication number: 20040018192
    Abstract: The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action. Namely, it provides an integrin expression inhibitor comprising, as an active ingredient, a sulfonamide compound represented by the following formula (I), a pharmacologically acceptable salt thereof or a hydrate of them.
    Type: Application
    Filed: July 18, 2002
    Publication date: January 29, 2004
    Inventors: Toshiaki Wakabayashi, Yasuhiro Funahashi, Naoko Hata, Taro Semba, Yuji Yamamoto, Toru Haneda, Takashi Owa, Akihiko Tsuruoka, Junichi Kamata, Tadashi Okabe, Keiko Takahashi, Kazumasa Nara, Shinichi Hamaoka, Norihiro Ueda
  • Patent number: 6673787
    Abstract: The present invention creates a novel antiangiogenic agent and provides an antitumor agent which shows high safety as compared with conventional antitumor agents, has a sure effect and is able to be administered for a long period. That is, it provides an indole compound represented by the following formula (I), its pharmacologically acceptable salt or hydrates thereof. In the formula, R1 represents hydrogen atom, a halogen atom or cyano group; R2 and R3 are the same as or different from and each represents hydrogen atom, a C1-C4 lower alkyl group or a halogen atom; R4 represents hydrogen atom or a C1-C4 lower alkyl group; and the ring A represents cyanophenyl group, aminosulfonylphenyl group, aminopyridyl group, aminopyrimidyl group, a halopyridyl group or cyanothiophenyl group, provided that the case where all of R1, R2 and R3 are hydrogen atoms, where both R2 and R3 are hydrogen atoms or where the ring A is aminosulfonyl group and both R1 and R2 are halogen atoms is excluded.
    Type: Grant
    Filed: March 18, 2002
    Date of Patent: January 6, 2004
    Assignee: Eisai Co., Ltd.
    Inventors: Toru Haneda, Akihiko Tsuruoka, Junichi Kamata, Tadashi Okabe, Keiko Takahashi, Kazumasa Nara, Shinichi Hamaoka, Norihiro Ueda, Takashi Owa, Toshiaki Wakabayashi, Yasuhiro Funahashi, Taro Semba, Naoko Hata, Yuji Yamamoto, Yoichi Ozawa, Noako Tsukahara
  • Patent number: 6638964
    Abstract: The present invention creates a novel antiangiogenic agent and provides an antitumor agent which shows high safety as compared with conventional antitumor agents, has a sure effect and is able to be administered for a long period. That is, it provides an indole compound represented by the following formula (I), its pharmacologically acceptable salt or hydrates thereof: In the formula, R1 represents hydrogen atom, a halogen atom or cyano group; R2 and R3 are the same as or different from and each represents hydrogen atom, a C1˜C4 lower alkyl group or a halogen atom; R4 represents hydrogen atom or a C1˜C4 lower alkyl group; and the ring A represents cyanophenyl group, aminosulfonylphenyl group, aminopyridyl group, aminopyrimidyl group, a halopyridyl group or cyanothiophenyl group, provided that the case where all of R1, R2 and R3 are hydrogen atoms, where both R2 and R3 are hydrogen atoms or where the ring A is aminosulfonyl group and both R1 and R2 are halogen atoms is excluded.
    Type: Grant
    Filed: March 18, 2002
    Date of Patent: October 28, 2003
    Assignee: Eisai Co., Ltd.
    Inventors: Toru Haneda, Akihiko Tsuruoka, Junichi Kamata, Tadashi Okabe, Keiko Takahashi, Kazumasa Nara, Shinichi Hamaoka, Norihiro Ueda, Takashi Owa, Toshiaki Wakabayashi, Yasuhiro Funahashi, Taro Semba, Naoko Hata, Yuji Yamamoto, Yoichi Ozawa, Noako Tsukahara
  • Publication number: 20030144507
    Abstract: The present invention provides a sulfonamide- or sulfonylurea-containing heterocyclic compounds. Specifically, it provides a heterocyclic compound represented by the formula (I), a pharmacologically acceptable salt thereof or a hydrate of them.
    Type: Application
    Filed: June 10, 2002
    Publication date: July 31, 2003
    Inventors: Toru Haneda, Akihiko Tsuruoka, Junichi Kamata, Tadashi Okabe, Keiko Takahashi, Kazumasa Nara, Shinichi Hamaoka, Norihiro Ueda, Toshiaki Wakabayashi, Yasuhiro Funahashi, Taro Semba, Naoko Hata, Yuji Yamamoto, Yoichi Ozawa, Naoko Tsukahara, Takashi Owa
  • Patent number: 6469043
    Abstract: The present invention creates a novel antiangiogenic agent and provides an antitumor agent which shows high safety as compared with conventional antitumor agents, has a sure effect and is able to be administered for a long period. That is, it provides an indole compound represented by the following formula (I), its pharmacologically acceptable salt or hydrates thereof. In the formula, R1 represents hydrogen atom, a halogen atom or cyano group; R2 and R3 are the same as or different from and each represents hydrogen atom, a C1˜C4 lower alkyl group or a halogen atom; R4 represents hydrogen atom or a C1˜C4 lower alkyl group; and the ring A represents cyanophenyl group, aminosulfonylphenyl group, aminopyridyl group, aminopyrimidyl group, a halopyridyl group or cyanothiophenyl group, provided that the case where all of R1, R2 and R3 are hydrogen atoms, where both R2 and R3 are hydrogen atoms or where the ring A is aminosulfonyl group and both R1 and R2 are halogen atoms is excluded.
    Type: Grant
    Filed: September 28, 2000
    Date of Patent: October 22, 2002
    Assignee: Eisai Co., Ltd.
    Inventors: Toru Haneda, Akihiko Tsuruoka, Junichi Kamata, Tadashi Okabe, Keiko Takahashi, Kazumasa Nara, Shinichi Hamaoka, Norihiro Ueda, Takashi Owa, Toshiaki Wakabayashi, Yasuhiro Funahashi, Taro Semba, Naoko Hata, Yuji Yamamoto, Yoichi Ozawa, Noako Tsukahara
  • Publication number: 20020128480
    Abstract: The present invention creates a novel antiangiogenic agent and provides an antitumor agent which shows high safety as compared with conventional antitumor agents, has a sure effect and is able to be administered for a long period. That is, it provides an indole compound represented by the following formula (I), its pharmacologically acceptable salt or hydrates thereof.
    Type: Application
    Filed: March 18, 2002
    Publication date: September 12, 2002
    Applicant: Eisai Co., Ltd.
    Inventors: Toru Haneda, Akihiko Tsuruoka, Junichi Kamata, Tadashi Okabe, Keiko Takahashi, Kazumasa Nara, Shinichi Hamaoka, Norihiro Ueda, Takashi Owa, Toshiaki Wakabayashi, Yasuhiro Funahashi, Taro Semba, Naoko Hata, Yuji Yamamoto, Yoichi Ozawa, Noako Tsukahara
  • Publication number: 20020128483
    Abstract: The present invention creates a novel antiangiogenic agent and provides an antitumor agent which shows high safety as compared with conventional antitumor agents, has a sure effect and is able to be administered for a long period. That is, it provides an indole compound represented by the following formula (I), its pharmacologically acceptable salt or hydrates thereof.
    Type: Application
    Filed: March 18, 2002
    Publication date: September 12, 2002
    Applicant: Eisai Co., Ltd.
    Inventors: Toru Haneda, Akihiko Tsuruoka, Junichi Kamata, Tadashi Okabe, Keiko Takahashi, Kazumasa Nara, Shinichi Hamaoka, Norihiro Ueda, Takashi Owa, Toshiaki Wakabayashi, Yasuhiro Funahashi, Taro Semba, Naoko Hata, Yuji Yamamoto, Yoichi Ozawa, Noako Tsukahara